(EAY 131-P MATCH): Phase II Study of PI3K Beta Specific Inhibitor, GSK2636771, in Patients with Tumors with PTEN Loss by IHC
Description: 
The mechanisms underlying cancer are marked by complex aberrations that activate critical cellular signaling pathways in tumorigenesis. Identifying actionable molecular aberrations has been critical to several major therapeutic advances in cancer medicine. Examples include BCR-ABL fusion in chronic myeloid leukemia (CML), epidermal growth factor (EGFR) mutations and EML4-ALK fusion in non-small cell lung cancer, and BRAF mutations in melanoma. The phosphatidylinositol 3-kinase/protein kinase-B/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling cascade is one of the most important intracellular pathways, which is frequently activated in diverse cancers. PI3K/AKT/mTOR signaling regulates cell proliferation, differentiation, cellular metabolism, and cytoskeletal reorganization leading to apoptosis and cancer cell survival. Activation of the PI3K/AKT/mTOR signaling pathway mediated through molecular aberrations such as loss of PTEN function is instrumental in promoting tumor development as well as resistance to anticancer therapies
Study Number: 

NCG 275215 P

Phase: 
2
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT02465060

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.